. . "Very poor absorption from gastrointestinal tract."@en . . . "Colistimethate is a surface active agent which penetrates into and disrupts the bacterial cell membrane. Colistimethate is polycationic and has both hydrophobic and lipophilic moieties. It interacts with the bacterial cytoplasmic membrane, changing its permeability. This effect is bactericidal. There is also evidence that polymyxins enter the cell and precipitate cytoplasmic components, primarily ribosomes."@en . . . . . "2-3 hours following either intravenous or intramuscular administration in adults and in the pediatric population, including premature infants."@en . . . "8068-28-8"@en . . . . . . . . . . . . . . . . . "Colistin sodium methanesulfonate"@en . . . . . " "@en . "Gram-negative bacilli"@en . . "Oral LD₅₀ in rats is 5450 mg/kg. Overdosage with colistimethate can cause neuromuscular blockade characterized by paresthesia, lethargy, confusion, dizziness, ataxia, nystagmus, disorders of speech and apnea. Respiratory muscle paralysis may lead to apnea, respiratory arrest and death."@en . "approved"@en . . . "Colistimethate is an antibiotic that has been shown to have bactericidal activity against aerobic gram-negative microorganisms. Colistimethate is particularly indicated when the infection is caused by sensitive strains of Pseudomonas aeruginosa. "@en . . "Colistimethate"@en . . . . . . "For the treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa."@en . . . . " "@en . . . . . . . . . . . . . .